EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette–Guérin and Immune Checkpoint Inhibitors

Seung-Woo Baek iD, Sun-Hee Leem

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25073800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Seung-Woo Baek und 1 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Mycobacterium bovis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 75% of bladder cancer cases originate as non-muscle-invasive bladder cancer (NMIBC). Despite initial diagnosis, NMIBC commonly recurs, with up to 45% advancing to muscle-invasive bladder cancer (MIBC) and metastatic disease. Treatment for high-risk NMIBC typically includes procedures like transurethral resection and, depending on recurrence risk, intravesical chemotherapy or immunotherapy such as Bacillus Calmette–Guérin (BCG). However, persistent shortages of BCG necessitate alternative first-line treatments. We aim to use a multi-gene signature in high-risk NMIBC patients to determine whether patients may benefit from immune checkpoint inhibitors (ICIs) as an alternative to BCG and to evaluate their clinical utility. The multi-gene signature obtained from the three independent NMIBC cohorts was applied to stratify the UROMOL2016 cohort (n = 476) using consensus clustering. Each subtype was distinguished by biological pathway analysis. Validation analysis using a machine learning algorithm was performed in six independent cohorts including the BRS (n = 283) cohort treated with BCG and the IMvigor210 (n = 298) clinical trials treated with PD-L1 inhibitors. Based on consensus cluster analysis, NMIBC patients in the UROMOL2016 cohort were classified into three classes exhibiting distinguished characteristics, including DNA damage repair (DDR). Survival analysis showed that the NMIBC-DDR class had the highest rates of disease progression (progression-free survival, p = 0.002 by log-rank test) in the UROMOL cohort and benefited from BCG and ICIs (respectively, p = 0.02 and p = 0.03 by log-rank test). This study suggests that the multi-gene signature may have a role in identifying high-risk NMIBC patients and improving the responsiveness of ICIs. Additionally, we propose immunotherapy as a new first-line treatment for patients with high-risk NMIBC because of the shortage of BCG supply. It is important to help more patients prioritize cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsMycobacterium bovisHumansImmune Checkpoint InhibitorsBCG VaccineImmunotherapy

Stichwörter der Autor:innen

BCG shortagehigh-risk non-muscle-invasive bladder cancerimmunotherapymolecular subtypeprognosisthe multi-gene signature

Substanzen

Immune Checkpoint InhibitorsBCG Vaccine

Autor:innen und Institutionen

  • Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.
  • Department of Biomedical Sciences, Dong-A University, Busan 49315, Republic of Korea.
  • Department of Health Sciences, The Graduate School of Dong-A University, Busan 49315, Republic of Korea.

ORCID-Profile: Seung-Woo Baek

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Baek, S. W., & Leem, S. H. (2024). A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette–Guérin and Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25073800

Vancouver

Baek SW, Leem SH. A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette–Guérin and Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25073800

BibTeX
@article{Baek2024,
  author = {Baek, Seung-Woo and Leem, Sun-Hee},
  title = {A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette–Guérin and Immune Checkpoint Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25073800}
}
Kostenlos starten →